Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Lags Revenue Estimates
Portfolio Pulse from
Nurix Therapeutics, Inc. (NRIX) reported a Q4 loss of $0.75 per share, which was worse than the Zacks Consensus Estimate of a $0.67 loss. This is a slight improvement from the $0.77 loss per share reported a year ago.
January 28, 2025 | 11:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Nurix Therapeutics reported a Q4 loss of $0.75 per share, missing the Zacks Consensus Estimate of a $0.67 loss. This is a slight improvement from the previous year's $0.77 loss per share.
The reported loss per share of $0.75 is worse than the expected $0.67, which is likely to negatively impact the stock price in the short term. However, the loss is slightly better than the previous year's $0.77, which may mitigate some negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100